Isolated limb perfusion as a treatment option for rare types of tumours |
| |
| Authors: | Valerio Belgrano Ilan Ben-Shabat Peter Bergh |
| |
| Affiliation: | 1. Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden;2. Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, IRCCS AOU San Martino-IST University-Hospital, Genoa, Italy;3. Department of Orthopaedics, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden |
| |
| Abstract: | ![]()
Background: Isolated limb perfusion (ILP) is an established and effective treatment for advanced melanoma and soft tissue sarcomas of the extremities with a high overall response rate. The aim of this study was to describe our experience of ILP for more rare types of tumours.Methods: Patients with Merkel cell carcinoma (MCC) (n?=?4), squamous cell carcinoma (SCC) (n?=?2), B-cell lymphoma (n?=?1), desmoid tumours (n?=?3), pigmented villonodular synovitis (PVNS) (n?=?1) and giant cell tumour (n?=?1) were treated with ILP and analysed retrospectively.Results: The four patients with in-transit MCC had three complete responses (CR) and one partial response (PR); the two patients with SCC had one CR and one stable disease (SD); the patients with desmoid tumours had two PR and one SD. A CR was also observed for the patient with a giant cell tumour, but the patient with PVNS had a SD. The patient with cutaneous metastases of B-cell lymphoma showed a CR, however with rapid systemic progression. Local toxicity according to Wieberdink was grade II in 10 patients (83%) and grade III in two patients (17%).Conclusions: These results show that ILP can be used as a treatment option also for more rare disease entities when other treatments have failed. |
| |
| Keywords: | Advanced status isolated limb perfusion local control rare tumours |
|
|
